Lu, E.R.; Hoo, C.P.L.; Cheung, H.M.; Wong, I.W.C.; Fung, K.F.K.; Chang, S.L.Y.; Lee, A.C.W.; Fu, E.C.H.; Ku, D.T.L.; Yau, J.P.W.;
et al. End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta. Cancers 2026, 18, 1028.
https://doi.org/10.3390/cancers18061028
AMA Style
Lu ER, Hoo CPL, Cheung HM, Wong IWC, Fung KFK, Chang SLY, Lee ACW, Fu ECH, Ku DTL, Yau JPW,
et al. End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta. Cancers. 2026; 18(6):1028.
https://doi.org/10.3390/cancers18061028
Chicago/Turabian Style
Lu, Evelyn R., Calvin P. L. Hoo, Ho Ming Cheung, I. W. C. Wong, K. F. Kevin Fung, Sylvia L. Y. Chang, Anselm C. W. Lee, Eric C. H. Fu, Dennis T. L. Ku, Jeffrey P. W. Yau,
and et al. 2026. "End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta" Cancers 18, no. 6: 1028.
https://doi.org/10.3390/cancers18061028
APA Style
Lu, E. R., Hoo, C. P. L., Cheung, H. M., Wong, I. W. C., Fung, K. F. K., Chang, S. L. Y., Lee, A. C. W., Fu, E. C. H., Ku, D. T. L., Yau, J. P. W., Shing, M. M. K., Mak, C. Y. K., Liu, A. P. Y., & Chan, G. C. F.
(2026). End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta. Cancers, 18(6), 1028.
https://doi.org/10.3390/cancers18061028
